Berobenatide for Osteoarthritis
What You Need to Know Before You Apply
What is the purpose of this trial?
The purpose of this clinical study is to learn about the safety and effects of berobenatide (PF-08653944) for the treatment of knee osteoarthritis in adults with overweight or obesity with and without type 2 diabetes. The study will last 52 weeks and compare the effects of berobenatide compared to placebo on knee pain, physical function, and body weight. Study activities will include blood tests, knee pain assessment, physical function questionnaires and body measurements.
Who Is on the Research Team?
Pfizer CT.gov Call Center
Principal Investigator
Pfizer
Are You a Good Fit for This Trial?
This trial is for adults who have knee osteoarthritis and are overweight or obese, with or without type 2 diabetes. Participants should not have other major health issues that could interfere with the study.Inclusion Criteria
Exclusion Criteria
What Are the Treatments Tested in This Trial?
Interventions
- Berobenatide
Trial Overview
The study tests a new drug called berobenatide, given once a week by injection, compared to a placebo (inactive treatment) over one year. It looks at effects on knee pain, movement ability, and body weight.
How Is the Trial Designed?
4
Treatment groups
Experimental Treatment
Placebo Group
Berobenatide Once Weekly
Berobenatide Once Weekly
Berobenatide Once Weekly
Placebo
Find a Clinic Near You
Who Is Running the Clinical Trial?
Pfizer
Lead Sponsor
Albert Bourla
Pfizer
Chief Executive Officer since 2019
PhD in Biotechnology of Reproduction, Aristotle University of Thessaloniki
Patrizia Cavazzoni
Pfizer
Chief Medical Officer
MD from McGill University
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.